Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis.

Takatoshi Anno, Kazutoshi Murakami, Shuhei Nakanishi, Jun Wada, Kohei Kaku, Hideaki Kaneto, Shinji Kamei

Abstract readCase Reports

In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Takatoshi AnnoDepartment of Diabetic Medicine, Kurashiki Central Hospital, Japan.

Kazutoshi MurakamiDepartment of Diabetic Medicine, Kurashiki Central Hospital, Japan.

Shuhei NakanishiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.

Jun WadaDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.

Kohei KakuDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.

Hideaki KanetoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.

Shinji KameiDepartment of Diabetic Medicine, Kurashiki Central Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced hypercholesterolemia is well known to cause side effects, such as secondary hypercholesterolemia. Many of these drugs are essential for long-term use and are difficult to replace; therefore, they are continued even when associated with hypercholesterolemia. Mesalazine is the first-line drug used for treating ulcerative colitis. We herein report a case of severe hypercholesterolemia following mesalazine administration in a patient with ulcerative colitis. In this case, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor was effective in dramatically improving severe hypercholesterolemia. Clinicians should therefore be aware of the possibility of severe hypercholesterolemia caused by mesalazine for educational purposes.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalColitis, UlcerativeHypercholesterolemiaMesalamineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsSeverity of Illness IndexAnti-Inflammatory Agents, Non-SteroidalHydroxymethylglutaryl-CoA Reductase InhibitorsMesalamineHMG-CoA reductase inhibitorhypercholesterolemiamesalazineulcerative colitis

Identifiers

PMID41443871

DOI10.2169/internalmedicine.6599-25

PMCPMC13627477

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.